R92.00 incl VAT
The clinical landscape of diabetes is undergoing a shift as we recognize that over half of type 1 diabetes cases now occur in adulthood. For care teams, this presents a formidable diagnostic challenge: in adults, type 2 diabetes is so prevalent that T1D is frequently misclassified, leading to suboptimal management
Our session will explore “the “palette of risk” that defines T1D: complex interplay of genetics, islet autoantibodies and metabolic markers that aggregate into unique disease networks. We will move beyond the traditional “one-size-fits-all” model to examine T1D as a heterogeneous condition where age of onset significantly influences disease aggressiveness and the rate of C-peptide loss.
Clinically, we must grapple with the Bayesian reality of diagnosis, that even highly specific tests, such as islet autoantibodies, have a modest positive predictive value in populations where the prior probability of T1D is low. Philosophically, this invites us to view diagnosis not as a static label, but as a probabilistic journey. We must balance the scientific rigor of high-specificity biomarkers with the human necessity of personalized care, acknowledging that “type 1” and “type 2” may represent fuzzy clusters rather than rigid silos. As we enter the era of disease-modifying therapies like teplizumab, our ability to accurately stage and “unmask” the true phenotype of adult-onset T1D becomes not just a clinical goal, but an ethical imperative to preserve beta-cell function.
(Please note that subscribing here does NOT register you for any CDE Course)
